Veeva Systems Inc.
VEEV · NYSE
$264.01+$77.1741.66%
$265.60+$1.590.60%
VEEV · NYSE
Veeva Systems sells cloud software designed for the life-sciences industry, serving pharmaceutical, biotechnology, and related healthcare companies. Its platform supports commercial, clinical, regulatory, quality, and other enterprise workflows, with subscription software providing the core recurring-revenue model. The company also provides implementation, professional, and related services. The supplied evidence does not disclose the current contribution of individual product segments or customer categories, so segment percentages cannot be stated. Veeva generated $3.2 billion of FY2026 revenue and $0.9 billion of net income, up from $2.7 billion and $0.7 billion, respectively, in FY2025.
Veeva Systems rose $10.66, or 5.30%, from $201.20 to $211.86 over the supplied week. Trading was volatile: the stock gained 3.33% on July 29, gave back nearly all of that advance with a 3.05% decline on July 30, then recovered through July 31 and August 3 before adding another 2.72% on August 4. The evidence does not identify a company-specific operating announcement, earnings release, contract, or executive comment driving the rebound. Instead, the move occurred despite a reported Citigroup downgrade to Neutral and Wall Street Zen’s downgrade to Hold. Zacks noted that Veeva declined while the broader market improved on July 30, but no broader-market catalyst is supplied for the subsequent recovery.
